Akoya Biosciences Inc
AKYA1.290USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
64.29MMarket Cap
LossP/E TTM
More Details of Akoya Biosciences Inc Company
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research, and diagnostics. It offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).
Akoya Biosciences Inc Info
Ticker SymbolAKYA
Company nameAkoya Biosciences Inc
IPO dateApr 16, 2021
CEOMr. Brian Mckelligon
Number of employees205
Security typeOrdinary Share
Fiscal year-endApr 16
Address100 Campus Drive
CityMARLBOROUGH
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code01762
Phone18558968401
Websitehttps://www.akoyabio.com/
Ticker SymbolAKYA
IPO dateApr 16, 2021
CEOMr. Brian Mckelligon
Company Executives of Akoya Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Laurie Churchill
Ms. Laurie Churchill
Company Secretary
Company Secretary
--
--
Mr. Brian Keane
Mr. Brian Keane
Assistant Secretary
Assistant Secretary
--
--
Mr. Masoud Toloue
Mr. Masoud Toloue
President, Director
President, Director
--
--
Ms. Vandana Sriram
Ms. Vandana Sriram
Treasurer
Treasurer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Laurie Churchill
Ms. Laurie Churchill
Company Secretary
Company Secretary
--
--
Mr. Brian Keane
Mr. Brian Keane
Assistant Secretary
Assistant Secretary
--
--
Mr. Masoud Toloue
Mr. Masoud Toloue
President, Director
President, Director
--
--
Ms. Vandana Sriram
Ms. Vandana Sriram
Treasurer
Treasurer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Consumables
6.94M
41.73%
Instruments
5.03M
30.23%
Service and other revenue
4.61M
27.69%
Standalone software products
58.00K
0.35%
By RegionUSD
Name
Revenue
Proportion
North America
10.14M
60.93%
EMEA
3.92M
23.54%
APAC
2.58M
15.54%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumables
6.94M
41.73%
Instruments
5.03M
30.23%
Service and other revenue
4.61M
27.69%
Standalone software products
58.00K
0.35%
Shareholding Stats
Updated: Sat, Jul 12
Updated: Sat, Jul 12
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Quanterix Corp
61.18%
Telegraph Hill Partners
35.38%
aMoon Fund
9.77%
Blue Water Life Science Advisors, LP.
9.40%
Piper Sandler Merchant Banking Fund II, L.P.
7.08%
Shareholders
Shareholders
Proportion
Quanterix Corp
61.18%
Telegraph Hill Partners
35.38%
aMoon Fund
9.77%
Blue Water Life Science Advisors, LP.
9.40%
Piper Sandler Merchant Banking Fund II, L.P.
7.08%
Shareholder Types
Shareholders
Proportion
Corporation
68.26%
Private Equity
35.38%
Venture Capital
9.77%
Individual Investor
3.26%
Investment Advisor
0.03%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
185
71.27M
142.67%
-1.21M
2025Q1
196
68.63M
137.95%
+20.99M
2024Q4
199
41.06M
83.29%
-3.40M
2024Q3
197
40.69M
82.73%
-3.51M
2024Q2
196
39.09M
79.63%
-6.10M
2024Q1
193
41.56M
84.64%
-3.04M
2023Q4
185
41.33M
84.84%
-3.48M
2023Q3
186
40.25M
93.70%
-1.35M
2023Q2
199
40.60M
94.80%
+2.62M
2023Q1
182
34.73M
90.54%
-3.33M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Quanterix Corp
--
0%
+2.85M
-100.00%
Telegraph Hill Partners
--
0%
--
--
aMoon Fund
--
0%
+1.80M
-100.00%
Blue Water Life Science Advisors, LP.
--
0%
--
--
Piper Sandler Merchant Banking Fund II, L.P.
--
0%
--
--
BlackRock Institutional Trust Company, N.A.
--
0%
-1.02M
-100.00%
The Vanguard Group, Inc.
--
0%
-194.07K
-100.00%
McKelligon (Brian M)
--
0%
+724.43K
-100.00%
Paragon JV Partners, LLC
--
0%
--
--
Geode Capital Management, L.L.C.
--
0%
-321.32K
-100.00%
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Akoya Biosciences Inc?
The top five shareholders of Akoya Biosciences Inc are:
Quanterix Corp holds 0.00 shares, accounting for 0.00% of the total shares.
Telegraph Hill Partners holds 0.00 shares, accounting for 0.00% of the total shares.
aMoon Fund holds 0.00 shares, accounting for 0.00% of the total shares.
Blue Water Life Science Advisors, LP. holds 0.00 shares, accounting for 0.00% of the total shares.
Piper Sandler Merchant Banking Fund II, L.P. holds 0.00 shares, accounting for 0.00% of the total shares.
Quanterix Corp holds 0.00 shares, accounting for 0.00% of the total shares.
Telegraph Hill Partners holds 0.00 shares, accounting for 0.00% of the total shares.
aMoon Fund holds 0.00 shares, accounting for 0.00% of the total shares.
Blue Water Life Science Advisors, LP. holds 0.00 shares, accounting for 0.00% of the total shares.
Piper Sandler Merchant Banking Fund II, L.P. holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Akoya Biosciences Inc?
The top three shareholder types of Akoya Biosciences Inc are:
Quanterix Corp
Telegraph Hill Partners
aMoon Fund
Quanterix Corp
Telegraph Hill Partners
aMoon Fund
How many institutions hold shares of Akoya Biosciences Inc (AKYA)?
As of 2025Q2, 185 institutions hold shares of Akoya Biosciences Inc, with a combined market value of approximately 71.27M, accounting for 142.67% of the total shares. Compared to 2025Q1, institutional shareholding has increased by 4.72%.
What is the biggest source of revenue for Akoya Biosciences Inc?
In FY2025Q1, the Consumables business generated the highest revenue for Akoya Biosciences Inc, amounting to 6.94M and accounting for 41.73% of total revenue.
